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The interleukin-mediated Janus kinase (JAK)/STAT pathway plays a crucial role in carcinogenesis. Recently, increased STAT3 activity
was found in hepatocellular carcinoma and multiple myeloma in which there was silencing of SOCS-1 (suppressor of cytokine
signalling-1) by gene promoter hypermethylation. We investigated the expression level of interleukin-6 (IL-6) and SOCS-1 in gastric
cancer cell lines. Expression of SOCS-1 correlated with IL-6 level in most of the cell lines, except for AGS cells in which SOCS-1 was
absent despite a high level of IL-6 production. Methylation analysis by methylation-specific polymerase chain reaction and bisulphite
sequencing revealed that CpG island of SOCS-1 was densely methylated in AGS cells. Demethylation treatment by 50aza-
deoxycytidine restored SOCS-1 expression and also suppressed constitutive STAT3 phosphorylation in AGS cells. Moreover,
methylation of SOCS-1 was detected in 27.5% (11 of 40) of primary gastric tumours samples, 10% (one of 10) of adjacent noncancer
tissues but not in any (zero of nine) normal gastric mucosa. Methylation of SOCS-1 also correlated with the loss of mRNA expression
in some primary gastric cancers. In conclusion, this is the first report to demonstrate that hypermethylation of SOCS-1 led to gene
silencing in gastric cancer cell line and primary tumour samples. Downregulation of SOCS-1 cooperates with IL-6 in the activation of
JAK/STAT pathway in gastric cancer.
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Gastric cancer is the second most common cause of cancer death
worldwide (Pisani et al, 1993). One of the well recognised
environmental risk factors for gastric cancer is Helicobacter pylori
infection (Graham, 1997). Although this bacterium has been
classified as a type I carcinogen by the World Health Organisation
(Kuipers and Meuwissen, 1996), the mechanisms by which H.
pylori causes gastric cancer is not fully understood. It is recognised
that there is a strong inflammatory response in H. pylori-infected
gastric cancer tissues. In particular, upregulation of interleukin-6
(IL-6) levels is observed in gastric cancer tissue (Yamaoka et al,
1996, 2001). Furthermore, serum IL-6 levels is shown to correlate
with prognosis of gastric cancer patients (Wu et al, 1996). These
data suggest that the activation of IL-6 signalling pathway may be
important in the development of gastric cancer.
Interleukin-6 and other interleukin family proteins are thought
to be involved in host defense mechanism as well as cancer
development (Kabir and Daar, 1995; Wu et al, 1996; Schneider et al,
2000; Giri et al, 2001). The activation of IL-6 signal transduction
involves binding to its transmembrane receptor and subsequent
activation of the Janus kinase (JAK), which is followed by
phosphorylation of STAT (STAT1/3) (O’Shea et al, 2002).
Phosphorylated STAT protein then translocates into the nucleus
with subsequent activation of target genes. One of the STAT-
activated genes is SOCS-1 (suppressor of cytokine signalling-1).
Suppressor of cytokine signalling-1 and its family are proteins
containing the SH2 domains that interact with JAK and prevent
activation of STAT, as well as downregulate the JAK/STAT
signalling pathways (Endo et al, 1997; Starr et al, 1997).
Specifically, SOCS-1 can be rapidly upregulated by IL-6 and is
involved in the downregulation of the IL-6-induced activation of
STAT3 (Starr et al, 1997; Nicholson et al, 1999).
Recent findings suggest that the inactivation of SOCS-1 was one
of the targets in cancer development. Suppressor of cytokine
signalling-1 is downregulated by methylation of the CpG island in
human hepatocellular carcinoma (HCC), multiple myeloma and
pancreatic ductal neoplasm (Yoshikawa et al, 2001; Nagai et al,
2002; Fukushima et al, 2003; Galm et al, 2003; Okochi et al, 2003).
On the other hand, restoration of SOCS-1 suppressed growth in
HCC cell lines and oncogene-activated haematopoietic cells
(Yoshikawa et al, 2001; Rottapel et al, 2002). Taken together,
these data suggest that SOCS-1 functions as a tumour suppressor in
the JAK/STAT pathway.
In the present study, we found that there was downregulation of
SOCS-1 gene in gastric cancer cell line AGS due to gene promoter
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yhypermethylation. Furthermore, demethylation treatment by
50aza-deoxycytidine (50azaDC) not only restored SOCS-1 expres-
sion in AGS cell but also suppressed constitutive STAT3
phosphorylation. Methylation of SOCS-1 was detected in 27.5%
(11 of 40) of primary gastric tumours samples. We further showed
that downregulation of SOCS-1 correlated with the methylation
status in primary gastric cancer. This study provides evidence that
the activation of JAK/STAT pathway by aberrant SOCS-1 methyla-
tion in gastric cancer.
MATERIALS AND METHODS
Gastric cancer cell lines and tissues
Gastric cancer cell lines AGS (CRL-1739), SNU-16 (CRL-5974),
KATO III (HTB-103), and NCI-N87 (CRL-5822) were obtained
from the American Type Culture Collection (ATCC, Rockville, MD,
USA), while MKN28 (RCB1000) and MKN45 (RCB1001) were
obtained from Riken Cell Bank (Tsukuba, Japan). All cell lines
except Kato III were grown in RPMI 1640 medium (Gibco BRL,
Gaithersburg, MD, USA) supplemented with 10% fetal bovine
serum (FBS) (Gibco BRL). Kato III was grown in RPMI 1640
medium supplemented with 20% FBS. All cell lines were kept at
371C in a humidified incubator with 5% CO2 in air.
In all, 40 primary gastric tumour samples and 10 adjacent
noncancer tissues were obtained in Prince of Wales Hospital,
Shatin, Hong Kong. Nine normal gastric mucosa from individuals
without gastric cancer were also obtained as control. All patients
gave informed consent for obtaining the specimens. The median
age of gastric cancer patients at the time of diagnosis was 70 years
old (range from 34 to 83). The male to female ratio was 1.5:1. The
H&E-stained sections were reviewed by a pathologist to confirm
the diagnosis. In all, 19 cases were intestinal type, 17 cases were
diffuse type, and four cases were mixed-type gastric adenocarci-
noma.
DNA extraction
DNA from formalin-fixed paraffin-embedded sections were
extracted using High Pure PCR Template Preparation Kit
(Boehringer Mannheim, Indianapolis, IN, USA). For extraction of
cell lines DNA, phenol/chloroform method was used. H&E-stained
sections from each tumour sample were examined by an
experienced pathologist to confirm their histological diagnosis
and assess the tumour content. If tumour content was less than
80%, tumour content was enriched by microdissection using a fine
needle under a dissection microscope as described previously
(Chan et al, 2000).
Methylation-specific polymerase chain reaction (PCR)
(MSP) for SOCS-1
Extracted DNA was bisulphite modified by CpGenome DNA
Modification kit (Intergen, Purchase, NY, USA). The modified
DNA was subjected to MSP using specific primers for SOCS-1 as
described previously (Yoshikawa et al, 2001). Primer sequences,
annealing temperatures and the expected product size were listed
in Table 1. A measure of 2ml of bisulphite-modified DNA were
amplified in a total volume of 25ml containing 1 PCR buffer II
(Applied Biosystems, Foster City, CA, USA), 2mM MgCl2, 0.25mM
dNTP, 1mM of each primer and 1U of AmpliTaq Gold DNA
polymerase (Applied Biosystems, Foster City, CA, USA) at 951C for
10min, 38 cycles of 951C for 30s, 601C for 30s, and 721C for 30s,
followed by a final extension of 721C for 10min. In vitro
methylated DNA (IVD) (Intergen, Purchase, NY, USA) was used
as a positive control for methylation and water was used as a
negative control. A measure of 10ml of PCR products were loaded
onto nondenaturing 10% polyacrylamide gels. The gels were then
stained with ethidium bromide and visualised under UV
illumination.
Bisulphite sequencing for SOCS-1
Bisulphite-treated DNA was amplified using specific primers for
exon 1 region of SOCS-1 gene as reported by Yoshikawa et al
(Table 1). The PCR products were cloned into Topo TA cloning kit
(Invitrogen, Carlsbad, CA, USA). Five randomly picked clones
were sequenced using the dRhodamine Terminator Cycle Sequen-
cing Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA). The sequencing products were separated on an Applied
Biosystems 377 automated sequencer (Applied Biosystems, Foster
City, CA, USA) and analysed using Applied Biosystems sequencing
analysis software.
RNA isolation and reverse transcription–PCR (RT–PCR)
for SOCS-1 and IL-6
Total RNA was extracted from frozen human gastric tissues and
cell lines by TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total
RNA (2mg) was reverse transcribed into cDNA by MMLV reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). The expression of
SOCS-1 and IL-6 was examined by PCR using specific primer as
listed in Table 1. For amplification of IL-6, a touch-down PCR cycle
as described by Lin et al (2000a) was used. As an internal control,
amplification of b-actin was performed. The PCR products were
electrophoresed on a 1.5% agarose gel stained with ethidium
bromide and visualised under ultraviolet illumination.
Table 1 PCR primer sequences used
Primer Forward primer (50-30) Reverse primer (50-30)
Annealing
temperature
(1C)
Product
size (bp)
SOCS-1
MSP M: TTCGCGTGTATTTTTAGGTCGGTC M: CGACACAACTCCTACAACGACC 60 93
U: TTATGAGTATTTGTGTGTATTTTTAGGTTGGTT U: CACTAACAACACAACTCCTACAACAACCA 60 105
Bisulphite sequencing TGTAGGATGGTAGTATATAATTAGGTGGT TAATACTCCAACAACTCTAAAAAACAATC 60 471
RT–PCR CGCCTGCGGATTCTACTG AGCAGCTCGAAGAGGCAGT 60 227
IL-6
a CACACAGACAGCCACTCACCTC CTCAGGCTGGACTGCAGGAAC 65 495
b-actin GCATTTGCGGTGGACGATGGAGG GGTCACCCACACTGTGCCCATCTA 65 653
M¼methylated primer; U¼unmethylated primer; SOCS-1¼suppressor of cytokine signalling-1; MSP¼methylation-specific PCR; RT–PCR¼reverse transcription–
polymerase chain reaction; IL-6¼interleukin-6.
aTouch-down programme starting from 651C.
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In vitro IL-6 production from AGS gastric cancer cell line was
performed as described previously (Hwang et al, 2003). AGS
(5 10
5 cellsml
 1) were plated into 24-well plate and cultured for
2 days in triplicate. Interleukin-6 in the supernatant was measured
by Quantikine HS human IL-6 immunoassay (R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s instruc-
tions. The ELISA sensitivity of IL-6 is 0.15pgml
 1.
Demethylation treatment of gastric cancer cells
To determine if SOCS-1 expression can be restored by demethylat-
ing agent, gastric cancer cell lines were subjected to 50azaDC
treatment. Cells were plated and incubated for 4 days with 5mM of
50azaDC (Sigma Chemical Co, St Louis, MO, USA).
IL-6 and anti-IL-6 antibody treatment of gastric cancer
cells
After 24h of serum starvation, 10ngml
 1 of recombinant IL-6
(R&D systems, Minneapolis, MN, USA) was then added into AGS
cell for 15min and proteins were extracted for further analysis. For
antibody treatment, 10mgml
 1 of anti-IL-6 antibody (R&D
systems) was added into the medium for 24h. Cells were then
harvested for protein extraction and determination of the
phosphorylation status of STAT3.
Western blotting analysis for phospho-STAT3 and total
STAT3
Cells are washed with PBS and lysed on ice in buffer containing 1%
NP-40, 50mM Tris at pH 8, 150mM NaCl, 5mM EDTA, 10mgml
 1
of aprotinin and pepstatin, 100mgml
 1 of PMSF, and 100mM
NaVO5. Protein concentration was determined using the Bio-Rad
protein assay. Protein (50mg) are separated on 10% SDS–
polyacrylamide gel electrophoresis and transferred to nitrocellu-
lose membrane at 100V for 2h at 41C using Bio-Rad transfer unit.
The transfer buffers used are 25mM Tris, 192mM glycine, and 20%
methanol. After transfer, the blots are blocked in 10% milk (fatty
acid free) with TBS-T (0.1% Tween-20, 20mM Tris, 137mM NaCl,
and 1 M HCl). The blots are then hybridised with anti-phospho-
STAT3 or anti-STAT3 polyclonal antibody (Cell Signaling, Beverly,
MA, USA) in 1:1000 dilution overnight at 41C followed by washes
in TBS-T, and then incubated with horseradish peroxidase-
conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:2000 dilution for 1h at room temperature. After
several washes, blots are developed using ECL Western blotting
detection kit (Amersham Biosciences, Uppsala, Sweden).
RESULTS
Expression of IL-6 in gastric cancer cell lines
Expression of IL-6 in six gastric cancer cell lines was assessed by
RT–PCR. Our result showed that AGS, N87, and MKN45 expressed
IL-6 (Figure 1, Table 2), while MKN28 had barely detectable IL-6
expression. IL-6 expression was absent in KATOIII and SNU16.
Expression of SOCS-1 in gastric cancer cell lines
By RT–PCR analysis, SOCS-1 was expressed in MKN45, N87,
MKN28, and KATOIII (Figure 1, Table 2). Since IL-6 and other
cytokines are known to upregulate the level of SOCS-1 gene (Starr
et al, 1997; Song and Shuai, 1998; Schuringa et al, 2000), we also
examine IL-6 level in these cell lines. Expression of IL-6 were
noticed in MKN45, N87, and MKN28, suggesting that the SOCS-1
expression may be related to a negative feedback mechanism of
IL-6 activation in these cell lines. In SNU16, both SOCS-1 and IL-6
was not detected. Although KATO III does not express IL-6, other
cytokines may also upregulate SOCS-1 in this cell line. Notably,
despite a high level of IL-6 expression, SOCS-1 expression was not
found in AGS cells (Figure 1).
IL-6 protein production in AGS cell
To further confirm that IL-6 protein is produced in AGS cells, we
examined IL-6 level secreted by AGS cells by high-sensitivity
ELISA assay. Our result showed that IL-6 production in AGS cells
was 10047130ngml
 1.
Methylation of SOCS-1 in gastric cancer cell lines
By MSP among the six cancer cell lines, methylation of SOCS-1
could only be detected in AGS cell (Figure 2). Dense methylation
pattern in the CpG islands of the exon 1 region of AGS cells was
AGS
MKN45
MKN28
KATOIII
SNU16
N87
IL-6
SOCS-1
-actin
Figure 1 Expression of SOCS-1 and IL-6 in gastric cancer cell lines by
RT–PCR analysis. b-actin was performed as an internal control for loading.
Table 2 Status of SOCS-1 and IL-6 in gastric cancer cell line
SOCS-1
Cell line MSP
a RT–PCR IL-6
b
AGS M   ++
SNU-16 U   
MKN28
c U++
MKN45 U + +
KATO III U +  
N87 U + +
SOCS-1¼suppressor of cytokine signalling-1; MSP¼methylation-specific PCR; RT–
PCR¼reverse transcription–polymerase chain reaction; IL-6¼interleukin-6.
aResult
of methylation-specific PCR: M, methylated; U, unmethylated.
bExpression status of
IL-6 by RT–PCR.
cIL-6 was weakly expressed in MKN28.
M
AGS
MKN45
MKN28
KATOIII
SNU16
N87
UMUMU MUMUMU MUMU
IVD
Marker
H20
Figure 2 Methylation analysis of SOCS-1 in gastric cancer cell lines by
MSP PCR. U indicates the presence of unmethylated genes; M indicates the
presence of methylated genes. In vitro methylated DNA (IVD) was used as
a positive control for methylation and water (H2O) was used as a negative
control for PCR.
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were essentially free of methylation (Figure 3).
Demethylation study of SOCS-1 in the AGS gastric cancer
cell line
Demethylation study was carried out in the AGS cell. After
treatment with 50azaDC, expression of SOCS-1 was restored as
demonstrated by RT–PCR (Figure 4, lower panel). Furthermore,
MSP detected both methylated and unmethylated allele of SOCS-1,
indicating that demethylation of the gene occurred (Figure 4,
upper panel). These results confirmed that loss of expression of
SOCS-1 in the AGS cell was related to gene methylation.
STAT3 activation in AGS gastric cancer cell line
Constitutive activation of STAT3 was found in the AGS cells in
which IL-6 was highly expressed (Figure 5, lane 1). We further
restored SOCS-1 expression in AGS cell by treating the cell with
50azaDC. In addition to the re-expression of SOCS-1, it was
accompanied by reduction in phosphorylation of STAT3 (Figure 5,
lane 2). Pretreatment with anti-IL-6 antibody for 24h also resulted
in inhibition of phosphorylation of STAT3 but not as marked as
50azaDC treatment (Figure 5, lane 5). Addition of recombinant IL-6
in the medium for 15min resulted in the reactivation of STAT3
phosphorylation in 50azaDC-treated AGS cells (Figure 5, lane 4),
suggesting that IL-6 was responsible for STAT3 activation. Taken
together, these findings suggested that SOCS-1 play an important
role in the inhibition of IL-6-mediated STAT3 activation in AGS
gastric cancer cell line.
AGS
0 100 200 300 400 490
N87
MKN28
MKN45
SNU16
KATOIII
Figure 3 Bisulphite sequencing analysis of six gastric cell lines. Five randomly picked clones of PCR product from bisulphate-treated DNA were
sequenced for each cell line. Black and white squares represent methylated and unmethylated CpG site, respectively. The translational start site is indicated
as ‘0’.
MSP
RT−PCR
SOCS-1
-actin
M
AGS
H 2 O
AGS+
5M 5'azaDC
5M 5'azaDC
2M 5'azaDC
0M 5'azaDC
UM M UU
Figure 4 Demethylation treatment of AGS cell line using 50azaDC. AGS
cell was treated with 2 or 5mM of 50azaDC for 4 days. The methylation and
expression of SOCS-1 was determined by MSP analysis (upper panel) and
RT–PCR (lower panel).
5'azaDC
Anti-IL-6 Ab
IL-6 
p-STAT3 
STAT3 
-actin 
−
−−− −
−−
+ −−
−
+
++
+
Figure 5 Effect of various treatments on phosphorylation of STAT3
protein in AGS cells. After treatment, cells were harvested for protein
extraction and subjected to Western blot analysis with anti-phospho-
STAT3 antibody to examine the phosphorylation status of STAT3 protein.
As a control, the blot was also probed with total STAT3 and b-actin.
Starting from left, AGS cells were untreated (panel 1) or treated with
50azaDC for 4 days (panel 2); recombinant IL-6 for 15min (panel 3);
50azaDC for 4 days and then recombinant IL-6 for 15min (panel 4); or anti-
IL-6 antibody for 24h (panel 5).
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gastric cancer
Methylation of SOCS-1 was found in 27.5 % (11 of 40) of gastric
cancer samples and 10% (one of 10) of adjacent normal mucosa
(Figure 6). Among these 40 gastric cancer samples, no correlation
between methylation status of SOCS-1 with H. pylori status,
histological type or staging was observed (Table 3). On the other
hand, SOCS-1 methylation was not found in the normal gastric
mucosa from nine individuals without gastric cancer (Figure 6). To
further investigate the expression status of SOCS-1 in these gastric
cancer tissues, total RNA from 14 gastric cancer samples and the
corresponding normal tissues were extracted for RT–PCR
analysis. Downregulation of SOCS-1 was observed in two (14%)
gastric tumour tissues, which also showed SOCS-1 methylation
(Figure 7, Table 4). These result suggested that methylation of
SOCS-1 gene was responsible for the downregulation of the gene in
primary gastric cancer.
DISCUSSION
Activation of interleukin-mediated JAK/STAT pathway has been
recently described to play a crucial role in human cancer
development. Constitutive activation of STAT3 has been observed
in breast cancer, prostate cancer and leukaemia (Schuringa et al,
2000; Lin et al, 2000b; Campbell et al, 2001; Li and Shaw, 2002).
Recent studies also found that blockade of STAT3 activity by the
expression of the dominant-negative STAT3 can inhibit growth of
AGS gastric cancer cell line, thus further suggesting that JAK/STAT
may play an important role in development of gastric cancer
(Kanai et al, 2003). On the other hand, inactivation of the negative
regulator, SOCS-1, also leads to the activation of the JAK/STAT
pathway. Downregulation of SOCS-1 by gene promoter hyper-
methylation has been recently reported in 65% of HCC cell line,
62.9% of multiple myeloma patients samples and 31.6% of
pancreatic cancer cell lines with resultant activation of STAT3
(Yoshikawa et al, 2001; Fukushima et al, 2003; Galm et al, 2003).
Moreover, restoration of SOCS-1 suppresses tumour growth in
Ca29 Ca30 Ca31 Ca32 Ca33 Ca34 IVD
AN2 AN1 N5 N4 N3 N2 N1
H2O
H2O
UM M
U MU MU MU MU MU MU MU M
UM U M UMUMUMU M
Primary
Tumour
Normal
Tissue
U
Figure 6 Methylation analysis of SOCS-1 in primary gastric cancer
samples and normal samples by MSP. The upper panel displayed result of
cancer samples (Ca) and lower panel displayed the result of normal
samples (N) and adjacent noncancer samples (AN).
Table 3 Association between SOCS-1 methylation and clinicopatholo-
gical parameters of gastric cancer
Total no. SOCS-1 methylation (%)
a P-value
b
Sex 0.347
Male 24 6 (25.0)
Female 16 5 (31.3)
Age (years) 0.404
X60 26 8 (30.7)
o60 14 3 (21.4)
H. pylori status 0.305
Positive 19 4 (21.1)
Negative 21 7 (33.3)
Site 0.510
Antrum 21 6 (28.5)
Body 11 4 (36.3)
Cardiac 8 1 (12.5)
Staging
c 0.596
I 7 2 (28.5)
II 6 3 (50)
III 19 4 (21.1)
IV 7 2 (28.5)
Lauren classification 0.875
Intestinal type 19 4 (21.1)
Diffuse Type 17 5 (29.4)
Mixed type 4 2 (50.0)
SOCS-1¼suppressor of cytokine signalling-1.
aNumber of methylated cases,
numbers within parentheses are percentages.
bComparison were made by w
2-test
or Fisher’s exact test (SPSS 10.0).
cStaging according to American Joint Committee on
Cancer. Data (staging were not available in one case).
N
SOCS-1
-actin
Ca46
Ca42
Ca34
TN T Marker
NT
Figure 7 Expression of SOCS-1 in primary tumour and corresponding
normal tissue by RTPCR. Decreased expression of SOCS-1 was found in
tumour samples of case 34 where methylation of SOCS-1 was also found
(Figure 6). T indicates gastric cancer sample and N indicates corresponding
normal sample. Expression of b-actin was also performed (lower panel) to
ensure equal loading.
Table 4 Methylation and expression status of SOCS-1 in 14 primary
gastric cancer samples
SOCS-1
Case Type Site Methylation Expression
Ca21 Intestinal Antrum U NC
Ca22 Intestinal Cardiac U NC
Ca24 Diffuse Cardiac U NC
Ca27 Diffuse Body M Down
Ca28 Intestinal Body U NC
Ca32 Intestinal Body U NC
Ca33 Intestinal Body U NC
Ca34 Mixed Antrum M Down
Ca36 Mixed Antrum M NC
Ca38 Mixed Cardiac U NC
Ca41 Diffuse Cardiac U NC
Ca42 Intestinal Antrum U NC
Ca46 Intestinal Antrum U NC
Ca47 Diffuse Antrum U NC
SOCS-1¼suppressor of cytokine signalling-1; M¼methylated; U¼unmethylated;
NC, no change; Down, downregulation.
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Yoshikawa et al, 2001; Rottapel et al, 2002).
In this study, we have found that IL-6 was endogenously
expressed in several gastric cancer cell lines. Since expression of
IL-6 upregulates SOCS-1, which participates in the negative
regulation of the JAK/STAT pathway (Starr et al, 1997; Song and
Shuai, 1998; Losman et al, 1999; Schuringa et al, 2000), we further
analysed the expression of SOCS-1 in these gastric cancer cell lines.
Both IL-6 and SOCS-1 was not expressed in SUN-16 and the results
suggested that this pathway might not be involved in this cell line.
Concomitant expression of IL-6 and SOCS-1 can be observed in
most gastric cancer cell lines, except KATOIII and AGS cell. To
further confirm that IL-6 protein is produced in AGS cells, we
examined IL-6 level by ELISA assay. IL-6 level of 1004ngml
 1 is
found in condition medium of AGS cells, which is consistent with
previous report (Crawford et al, 2003). Nevertheless, it was
interesting to note that SOCS-1 was not expressed in AGS cells
despite the expression of IL-6. We then analysed the methylation
status of this gene in AGS cells. Methylation studies by both MSP
analysis and bisulphite sequencing confirmed that CpG island of
SOCS-1 was methylated in AGS cells but not other cell lines.
Although KATO III did not express IL-6, the high level of SOCS-1
detected may act as a negative regulation for other cytokines
expressed in this cell line (Haque et al, 2000; Cottet et al, 2001;
Naka et al, 2001; Eyles et al, 2002).
In order to investigate the functional consequences of SOCS-1
inactivation in JAK/STAT pathway, we analysed the phosphoryla-
tion status of STAT3 protein in AGS cells. Under the condition that
SOCS-1 was inactivated by methylation, STAT3 was in hyperpho-
sphorylated state. Restoring SOCS-1 expression by treating the cells
with demethylation agent, phosphorylation of STAT3 was effec-
tively suppressed. On the other hand, blocking the endogenous IL-6
by anti-IL-6 antibody can partially suppress STAT3 activity.
Furthermore, addition of recombinant IL-6 restored STAT3
phosphorylation in demethylated-AGS cell, thus suggesting that
IL-6 was responsible for STAT3 activation. Taken together, these
results suggested that SOCS-1 was important for the downregula-
tion of JAK/STAT signalling. Methylation-mediated SOCS-1 in-
activation enhanced IL-6-mediated activation of STAT3 in AGS cell.
Moreover, methylation of SOCS-1 can be detected in about 30%
of primary tumour tissues and 10% of adjacent normal tissues.
Downregulation of SOCS-1 was also observed in primary gastric
cancer with methylation of SOCS-1. Although downregulation of
SOCS-1 was not observed in one sample (Ca36) in which
methylation of SOCS-1 was detected, this discrepancy may be
due to heterogeneity of the tumours in which only a small portion
of tumour cells have SOCS-1 methylation. Nevertheless, in this
study, we have demonstrated that SOCS-1 was silenced by
hypermethylation in the AGS cell line and a subset of primary
gastric tumour tissues. It is also worth noting to point out that
hypermethylation of SOCS-1 was also found in 10% of adjacent
normal tissue and this observation suggest that SOCS-1 methyla-
tion may also be involved in the early gastric carcinogenesis
process.
Recently, we and others have found that eradication of H. pylori
in the stomach can reduce the risk of gastric cancer (Uemura et al,
1997; Saito et al, 2000; Sung et al, 2000). The current study may
provide clue to the underlying mechanism that H. pylori-mediated
cytokine expression-enhanced tumour progression in a subset of
gastric cancer where SOCS-1 was hypermethylated. Inhibition of
JAK/STAT pathway by demethylation treatment or by applying
specific JAK2 inhibitor may open up a new therapeutic strategy
against gastric cancer (De Vos et al, 2000; Burke et al, 2001;
Yoshikawa et al, 2001).
In summary, loss of expression of SOCS-1 in AGS cell line was
related to gene promoter hypermethylation. This phenomenon
together with endogenous IL-6 expression leads to the activation of
STAT3 protein. The increase of STAT3 activity together with
overexpression of cytokine in this gastric cancer cell line suggested
that alteration of JAK/STAT was important in a subset of gastric
cancer.
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